MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.
The ARIES-HM3 is an international, randomized, double-blind, placebo-controlled study of either aspirin (N=293) or placebo with Vitamin K antagonists (warfarin) therapy (n=296) in patients with advanced heart failure supported with a HeartMate 3 LVAD.
The ARIES-HM3 clinical study evaluated a new clinical approach to patient management, and the data is currently not reviewed by the FDA. Labeling changes related to the anticoagulation regimen have not been approved by the FDA at this time.
These journal articles help illustrate the clinical evidence for the HeartMate 3 LVAD with Full MagLev™ Flow Technology.